New Zealand markets open in 7 hours 37 minutes
  • NZX 50

    -59.81 (-0.54%)

    -0.0019 (-0.30%)

    -75.50 (-1.09%)
  • OIL

    +1.89 (+1.69%)
  • GOLD

    -1.00 (-0.05%)

Blepharitis Drugs in Development Pipeline Guide 2022 by Stages, Target, MoA, RoA, Molecule Type and Key Players -

·4-min read

DUBLIN, May 19, 2022--(BUSINESS WIRE)--The "Blepharitis Drugs in Development 2022 Update" report has been added to's offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 7 and 2 respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Report Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis.

  • The pipeline guide reviews pipeline therapeutics for Blepharitis by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Blepharitis therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Blepharitis therapeutics based on mechanism of action, drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis

Key Topics Covered:

Blepharitis - Overview

Therapeutics Development

  • Pipeline Overview

  • Pipeline by Companies

  • Products under Development by Companies

Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

Drug Profiles

Dormant Projects

Product Development Milestones

Featured News & Press Releases

  • Feb 08, 2022: Tarsus to host eye care leaders webcast on unmet needs in demodex blepharitis and potential of TP-03

  • Feb 02, 2022: Tarsus Completes enrollment for the pivotal phase 3 Saturn-2 trial of TP-03 to treat demodex blepharitis and secures $175 million credit facility

  • Nov 30, 2021: Nicox's positive post hoc results from NCX 4251 phase 2b Mississippi trial suggest path forward in dry eye disease

  • Nov 17, 2021: Nicox is granted patent for blepharitis product candidate NCX 4251 in Europe

  • Nov 04, 2021: Tarsus Pharmaceuticals, presents data from two pioneering studies on the prevalence and impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

  • Aug 31, 2021: AxeroVision announces phase 2 results for AXR-270 for treatment of dry eye disease associated with MGD

  • Jul 24, 2021: Tarsus Pharmaceuticals presents new Saturn-1 pivotal trial data and Titan real-world prevalence study results at ASCRS 2021

  • Jul 02, 2021: Nicox announces last patient completed NCX 4251 Mississippi phase 2b blepharitis trial

  • Jun 21, 2021: Tarsus Pharmaceuticals announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of demodex blepharitis

  • Jun 18, 2021: Tarsus Pharmaceuticals schedules conference call and webcast to announce saturn-1 phase 2b/3 pivotal trial results for TP-03 for the treatment of Demodex Blepharitis

  • Jun 01, 2021: Nicox's completes pre-defined enrollment of NCX 4251 Mississippi phase 2b Blepharitis trial

  • May 06, 2021: Tarsus Pharmaceuticals initiates Saturn-2, second pivotal phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis

  • May 03, 2021: Tarsus Pharmaceuticals presents results of pioneering Atlas study at ARVO 2021 annual meeting demonstrating the functional and psychosocial impact of demodex blepharitis

  • Apr 23, 2021: Nicox's NCX 4251 Mississippi Phase 2b blepharitis trial reaches 50% enrollment

  • Mar 17, 2021: Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction

Companies Mentioned

  • Aerie Pharmaceuticals Inc

  • Aperta Biosciences LLC

  • AxeroVision Inc

  • Azura Ophthalmics Pty Ltd

  • Formosa Pharmaceuticals Inc

  • Hovione FarmaCiencia SA

  • Merck & Co Inc

  • NicOx SA

  • NTC srl

  • Premark Pharma GmbH

  • Quorum Innovations LLC

  • Santen Pharmaceutical Co Ltd

  • Sol-Gel Technologies Ltd

  • Tarsus Pharmaceuticals Inc

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting